ALK and non-small cell lung carcinoma: The pivotal global, randomized, phase III ALEX study (BO28984, NCT02075840) confirmed the clinical benefit of first-line alectinib treatment for patients with ALK inhibitor naïve ALK-positive NSCLC [14].